Dr. Hayashi is the Lecturer of the Medical Oncology at Kindai University, Osaka-sayama, Japan and showing leadership in thoracic oncology team in Kindai University, as well as West Japan Oncology Group (WJOG). Dr Hayashi’s research interests is about immune-tumor micro environments in NSCLC with oncogenic driver mutations. Also, Dr Hayashi’s research combines clinical trials, with translational research and clinical research of novel therapeutic agents and immunotherapy in patients with lung cancer and several types of solid tumors. He has published numerous first- and corresponding author research papers in medical or basic scientific journals such as Journal of Clinical Oncology, JAMA oncology, Annals of Oncology, Journal of Thoracic Oncology, and Clinical Cancer Research. He has conducted several clinical trials as a principal investigator, including 1. Clinical trial about gene-profiling for cancer of unknown primary (JCO 2019, and JAMA Oncology 2020), 2. randomized phase 2 trial about efficacy of immune-check point inhibitors for EGFR mutated NSCLC (ASCO 2021), 3. phase 2 clinical trial about the alternative therapy with osimeritinib and afatinib for treatment-naïve advanced NSCLC with EGFR mutation (WCLC 2020), 4. biomarker-prospective study of nivolumab, and 5. phase 2 clinical trial of nivolumab for Cancer of Unknow Primary (presented in 2020 ASCO Special Clinical Symposium).

Bob Li, MD, PhD, MPH, FRACP, is an Australian medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center, New York, who specializes in early-phase drug development for lung cancers and solid tumors. Dr. Li is Chief Scientific Officer, MSK Direct, responsible for scientific innovation in MSK’s digital outreach strategy. He is also Co-Director of MSK’s multidisciplinary Thoracic Liquid Biopsy Program which is dedicated to developing the latest biotechnology on circulating biomarkers to transform the care of patients. Dr. Li is international principal investigator of multiple pivotal clinical trials of novel cancer therapies including “drugging the undruggable” KRAS - and targeting HER2 across multiple cancer types. These trials have transformed clinical practice guidelines, for which he has received awards from the American Society of Clinical Oncology and the American Association for Cancer Research. He has numerous first or senior author scientific publications in prestigious journals such as New England Journal of Medicine, Nature Medicine, Cancer Discovery, and Journal of Clinical Oncology. As MSK’s Physician Ambassador to China and Asia-Pacific, Dr. Li provides administrative leadership in international patient care, research and education programs to advance MSK’s mission abroad with transparency and impact. Through compassionate care and international collaboration, his career is dedicated to winning the global war on cancer and bringing real hope to patients.

Education
Graduated from Osaka University School of Medicine in 1984.

Professional experience
1984-1985 Resident, Department of Surgery, Osaka University Hospital
1985-1990 Residency of surgery at affiliated hospitals of Osaka University
1990-1992 Research fellow, Department of Surgery, Osaka University Hospital
1993-1996 Post-doctoral fellow, Howard Hughes Medical Institute, and Department of Pathology, Washington University, St. Louis, MO, USA
1996-2002 Assistant Professor, Department of Surgery, Osaka University Hospital
2002-2004 Department of Thoracic Surgery, National Hospital Organization Kinki Chuo Chest Disease Center
2004 Associate Professor, Department of Surgery, Osaka University Hospital
2007-2018 Professor, Department of General Thoracic Surgery, Osaka University
Graduate School of Medicine, Osaka University Hospital
2018- President (Hospital Director), Osaka Toneyama Medical Center, Osaka Japan

Degree
1984 MD
1994 PhD

Qualification
Board of surgery in Japan, Board of general thoracic surgery in Japan

Speciality
Surgery for lung cancer, thymic tumors, myasthenia gravis, and lung transplantation.
Basic research for oncology, immunology, and regenerative medicine.

Academic activity
Japanese Association of Thoracic Surgery (JATS), Board of Directors, 2009 – 2020
JACS, President, 2013-2017
JACS, Conference President of 36th Annual Conference (2019)
The Japan Lung Cancer Society, Board of Directors
Japan Surgical Society (JSS), Board of Directors
Japanese Association for Research on the Thymus (JART), President
Japanese National Registry of Lung Cancer, Ex-Director of Office
International Association for Study of Lung Cancer (IASLC), Member
IASLC, Board of SPFC, Thymic domain, 2018-
European Society of Thoracic Surgeons (ESTS), Member
ESTS, Program Committee 2016-2018
ESTS, International Councilor 2019-
European Association of Cardiothoracic Surgery (EACTS), Member
International Thymic Malignancy Interest Group, Member of Steering committee
International Society for Heart and Lung Transplantation, Member

Joachim Aerts is head of the department of Pulmonary Medicine at the Erasmus University Medical Center Rotterdam since 2018. His main research focus is on fundamental, translational and clinical research in immuno oncology, with a strong focus on lung cancer and mesothelioma. As PI and as co-investigator, prof. Aerts is involved in many studies both human and animal.
Prof. Aerts is leader of the core network on mesothelioma and board member of the European Reference Network on Rare Respiratory Diseases (ERN-Lung) and elected member of the board of directors of the International Association for the Study of Lung Cancer (IASLC). He is a frequent invited speaker on international conferences, and he is scientific committee member of multiple national and international societies, such as the NVALT, EORTC, ASCO, ESMO, ETOP, AACR, ERS and ATS.
Prof. Aerts is co-author of >200 articles in international peer reviewed scientific journals.

Arnaud Scherpereel (MD, PhD) is Professor of Respiratory Medicine and Head of the Pulmonary and Thoracic Oncology Department in Lille University Hospital (CHU), France for 12 years. He is routinely taking care of all respiratory patients but with a special focus in Thoracic Oncology and Pleural Diseases, including malignant pleural mesothelioma (MPM). He coordinates the French National network of expert centers for MPM (“NETMESO”).
Pr Scherpereel is highly involved in education at the local (assistant of the Dean of Lille Medical School), and national levels (past President of the French National College of Respiratory Medicine). In the European Respiratory Society, he was the Thoracic Oncology Assembly Secretary, and the chair of two European Taskforces on MPM management. He was the recipient of the 2019 Gold Medal for Thoracic Oncology. He also belongs to many Scientific Boards: IFCT, SPLF, ELCWP, IASLC, and mostly iMig (President, 2021-).
His main translational research topics include tumor angiogenesis, immunology and innovative anti-tumor treatments (cell therapy, PDT…), and non-invasive tools for lung cancer or MPM screening or early diagnosis (blood/exhaled breath biomarkers (VOCs), web-reported symptoms). He has been (Principal/Co-) Investigator of many clinical trials for MPM and lung cancer patients since 2003. Pr Scherpereel presented over 100 communications in international meetings. He is (co)author of more than 170 original publications in peer-reviewed journals, including internationally-known publications.

Dr. Jennifer Sauter is an Assistant Attending Pathologist in Thoracic Pathology and Cytopathology at Memorial Sloan Kettering Cancer Center. Her research interests are in pleural tumors as well as non small cell lung carcinoma and other tumors of the thorax. Most recently, she served as the lead author of the Diffuse Pleural Mesothelioma Section in the 2021 World Health Organization Classification of Thoracic Tumors.

Suresh Senan is Professor of clinical experimental radiotherapy at the Amsterdam University Medical Centers, The Netherlands. He trained in clinical oncology in the United Kingdom before moving to the Netherlands. His research has focused on lung cancer, stereotactic radiotherapy, immune checkpoint inhibitors, and Magnetic Resonance-guided adaptive radiotherapy. In 2016, he was awarded the Heine H. Hansen Award for his contributions to lung cancer care by the European Society of Medical Oncology and International Association for the Study of Lung Cancer.

Dr Paul Mitchell holds the positions of Medical Oncologist at the Olivia Newton-John Cancer, Wellness and Research Centre at Austin Health in Melbourne, Australia, Director of the North-Eastern Melbourne Integrated Cancer Service (Cancer Network) and Associate Professor at the University of Melbourne and University of Sydney. He is immediate past-President of the Australasian Lung Cancer Trials Group 2012-2016. He is Chair of the Lung Cancer Advisory Group of Cancer Australia, sits on the State Government’s Clinical Council and the Program Assessing Committee of the Health Research Council of New Zealand.
Dr Mitchell trained in medical oncology in Auckland, New Zealand, followed by two years as Senior Registrar at the Royal Marsden Hospital, UK, before completing a Doctor of Medicine degree based on 3 years work at the Institute of Cancer Research, UK. He moved to Melbourne in 1995.

Puneeth Iyengar is an Associate Professor and Chief of Thoracic Radiation Oncology at UT Southwestern Medical Center. He is also Associate Vice Chair for Research for the Department of Radiation Oncology and Co Leader of the Thoracic Program at UTSW. He has led programs investigating the use of local therapy (SBRT) in the setting of oligometastatic NSCLC (Iyengar et al, JCO 2014, Iyengar et al, JAMA Oncology 2017), hypofractionated therapies for stage III NSCLC (Iyengar et al, JAMA Oncology 2021) and is principal investigator of NRG LU 002, a phase III randomized trial assessing the benefits of local therapy on overall survival for stage IV NSCLC. Dr. Iyengar also runs an independent research laboratory studying cancer cachexia from a basic science and translational perspective. Dr. Iyengar trained at MD Anderson Cancer Center and received his MD, PhD degrees at Albert Einstein College of Medicine (NYC) and Bachelor of Science at MIT.

Dr. Nasser K. Altorki is the Chief of the Division of Thoracic Surgery at the New York-Presbyterian Hospital and is the David B. Skinner Professor of Cardiothoracic Surgery at Weill Cornell Medical College. He is also leader of the Experimental Therapeutics Program at the Sandra and Edward Meyer Cancer Center and Director of the Neuberger Berman Lung Cancer Research Center. Dr. Altorki completed his surgical and cardiothoracic training at the University of Chicago and joined the faculty at Weill Cornell Medicine in 1988. His professional interests include: the surgical treatment of esophageal and lung cancer, minimally invasive surgical techniques, and clinical trials in lung and esophageal cancer. Beyond his expertise in the surgical treatment of lung cancer and other chest malignancies, he has a longstanding interest in studying the immune landscape as well as immunotherapy for early stage lung cancer and has led several trials of adjuvant and neoadjuvant immunotherapy in early stage lung cancer. Dr. Altorki has served as the principle investigator on a number of national and international clinical trials, and has written numerous manuscripts and book chapters on lung cancer screening, staging and management of early lung cancer.
In 2007, Dr. Altorki established the Neuberger Berman Lung Cancer Research Program at Weill Cornell Medicine to support laboratory -based translational lung cancer research. The program’s primary objective is to explore the role of the tumor immune microenvironment in the initiation and progression of lung cancer. Over the years this program has matured and expanded to include four principal investigators. Dr. Altorki is also a member of numerous professional organizations, including the IASLC, the American Society of Clinical Oncology, the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American College of Surgeons, and the American Association of Cancer Research. Last, but not least, Dr. Altorki is a passionate patient advocate and thoughtful teacher and mentor to many residents, fellows, and junior faculty.